ALS Insurance Access Act, Before US Congress, Would End SSDI Waiting Period for ALS Patients

A bill that would waive the five-month waiting period for Social Security Disability Insurance (SSDI) for people with amyotrophic lateral sclerosis (ALS) — legislation supported by the ALS Association during its recent National ALS Advocacy Day in Washington, D.C. — has been introduced into the U.S. Congress. Called the ALS Disability Insurance Access…

In this video from Philly Philms, watch how the evolution of technological devices are now providing a way for people with low mobility in their upper-body to be able to communicate with other people with the help of assistive technology. Amyotrophic lateral sclerosis (ALS)…

This year’s ALS Association-sponsored Drug Company Working Group meeting — to review recent trial results and discuss new developments in the search for ALS treatments — was held in April as part of the 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, Canada, the world’s largest gathering…

Persistent environmental pollutants like pesticides are associated with amyotrophic lateral sclerosis (ALS) and may represent modifiable ALS disease risk factors, according to a study published online in JAMA Neurology, titled “Association of Environmental Toxins With Amyotrophic Lateral Sclerosis.” ALS is a progressive, fatal neurodegenerative disease. Persistent exposure to…

Ammar Al-Chalabi, a professor of Neurology and Complex Disease Genetics at King’s College London, was presented with the  Sheila Essey Award at a special session of the recent American Academy of Neurology (AAN) Annual Meeting dedicated to amyotrophic lateral sclerosis (ALS) research. He was selected to receive the $50,000 award by both the ALS Association…

During the Drug Company Working Group session at the recent American Academy of Neurology annual meeting in Vancouver, Canada, a top researcher from Cytokinetics gave an update on a new Phase 3 study of  tirasemtiv as a potential treatment for amyotrophic lateral sclerosis (ALS), and another from Biogen talked about a new trial to assess outcome measures in ALS…

The ALS Association and Prize4Life have launched a joint initiative worth $400,000, to award innovation in helping improve the lives of patients with amyotrophic lateral sclerosis (ALS). The ALS Assistive Technology Challenge will award the development of flexible, accessible technology for ALS patients to communicate. The importance of the challenge is explained…

Mutations in the SOD1 gene, a major copper-binding protein, are a known cause of familial amyotrophic lateral sclerosis (ALS). An extensive review from Keio University in Japan explores the possible role of copper homeostasis in SOD1-linked ALS, as seen in mice studies, and highlights the need for similar studies in people.

Tecla is for anyone who finds it difficult to use an iOS or Android touchscreen device. This includes people who have their mobility limited, especially their upper-body – such as amyotrophic lateral sclerosis (ALS) patients. Get Tecla is the youtube channel of The Tecla…

Scientists at Umeå University have found that  superoxide dysmutase (SOD1), a protein that may cause amylotophic lateral sclerosis (ALS) spreads and clumps when injected into mice. The protein deposits also cause ALS-like symptoms. The report, titled “Two superoxide dismutase prion strains transmit amyotrophic lateral sclerosis-like disease” appeared May 3, 2016…